Liraglutide Effect in Atrial Fibrillation

Inclusion Criteria:

- Male and female, age 18 or older

- Persistent atrial fibrillation defined as continuous AF that is sustained beyond 7
days (or atrial fibrillation in which a decision is made to cardiovert the patient
prior to 7 days).

- BMI ≥27 kg/m2

- Patient wishes to undergo catheter ablation procedure for treatment of atrial
fibrillation

- Receiving follow-up care at the University of Miami

Exclusion Criteria:

- Inability to sign informed consent

- Patients with paroxysmal atrial fibrillation and longstanding persistent atrial
fibrillation

- Prior ablation for atrial fibrillation

- Patients not appropriate candidates for catheter ablation such as those with AF due to
acute or chronic precipitating medical conditions, for example hypothyroidism and
hyperthyroidism, significant pulmonary disease, pulmonary embolism, left atrial
thrombus, class IV heart failure)

- Patients with a life expectancy <1 year

- Patients with a serious medical condition (for example, recent cancer with
chemotherapy or radiation therapy within 4 weeks prior to entering the study) who have
not recovered from adverse events due to agents administered more than 4 weeks
earlier.

- Known contraindications to Liraglutide, such as previous history of pancreatitis or
medullary thyroid carcinoma

- Personal or family history of multiple endocrine neoplasia

- Known serious hypersensitivity reaction to Liraglutide

- Patients using insulin, sulfonylureas, glitazones, sodium-glucose transporters 2
inhibitors (SGLT2i), other Glucagon-like peptide analogues or dipeptidyl peptidase 4
inhibitors

- Type 1 diabetes, defined by American Diabetes Association criteria, history of
diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes due to
pancreatitis or pancreatectomy

- Pregnant women

- Women who are breast-feeding or intend to become pregnant